tci Part B Insider - 2005 Issue 6

Coverage: 'Off-Label' Cancer Drug Trials May Run Off Rails, Providers Worry

Some think that expansion will actually derail 2000 advanceA Medicare coverage decision to expand coverage for some chemotherapy drugs should seem like a good thing.But the Centers for Medicare and Medicaid Services' plan to boost coverage for four colorectal cancer drugs ignited a blaze of controversy. CMS proposed to cover routine patient care costs of clinical trials involving "off-label" uses of oxaliplatin, irinotecan, bevacizumab and cetuximab. The nine clinical trials would look into the effectiveness of these drugs in non-recurring colorectal cancer. Medicare already covers the drugs for colorectal cancer that resists other treatments.But cancer providers worried...

To read the full article, sign in and subscribe to tci Part B Insider.


Keep pace with evolving Medicare regulations with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI’s Part B Insider will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4800 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles

This feature is currently unavailable for online purchase. For more information, please call 801-770-4203 or Contact Us.

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.